Related Experiment Video

Updated: May 17, 2026

Experimental Metastasis Assay
08:28

Experimental Metastasis Assay

Published on: August 24, 2010

Ror2-Src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE

Shan-Shan Lai1, Bin Xue, Yang Yang

  • 1Jiangsu Key Laboratory for Molecular and Medical Biotechnology, Nanjing Normal University, and Medical School of Nanjing University, Nanjing, China.

Cancer Genetics
|November 13, 2012
PubMed

Insights

Receptor tyrosine kinase Ror2 promotes melanoma metastasis via Src kinase signaling. Neurotrophin receptor-interacting MAGE homologue (NRAGE) inhibits this process, suggesting Ror2 and NRAGE as potential therapeutic targets for melanoma.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Biology

Background:

  • Receptor tyrosine kinase (RTK) Ror2 is crucial for developmental processes and Wnt5a-induced cell migration.
  • The role of Ror2 in noncanonical Wnt signaling and cancer metastasis remains largely unexplored.

Purpose of the Study:

  • To investigate the function of Ror2 in melanoma metastasis.
  • To elucidate the molecular mechanisms underlying Ror2-mediated cell migration and its regulation.

Main Methods:

  • Comparative analysis of Ror2 expression in high and low metastatic melanoma cells.
  • Manipulation of Ror2 expression (overexpression and knockdown) to assess its impact on metastasis and migration.
  • Investigation of the interaction between Ror2, Src kinase, and NRAGE using biochemical assays.

Main Results:

  • Ror2 expression is elevated in highly metastatic B16-BL6 melanoma cells.
  • Ror2 overexpression enhances B16 cell metastasis, while Ror2 knockdown reduces B16-BL6 cell migration.
  • Ror2-mediated cell migration is dependent on Src kinase activity and involves interaction with Src's SH1 domain.
  • NRAGE inhibits Ror2-mediated migration by disrupting the Ror2-Src interaction and decreasing Src and focal adhesion kinase (FAK) activity.

Conclusions:

  • Ror2 promotes melanoma tumorigenesis and metastasis through a Src-dependent pathway.
  • NRAGE negatively regulates Ror2-mediated metastasis, highlighting a novel inhibitory mechanism.
  • Ror2 and its interaction with Src, modulated by NRAGE, represent potential therapeutic targets for melanoma treatment.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs07:31

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs

Published on: May 24, 2016

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...